TKI-话题@MedSci

#TKI#

128篇内容 | 3901人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1384243, encodeId=43f9138424364, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Thorac Cancer：EGFR突变肺癌EGFR-TKIs治疗进展后应用免疫检查点抑制剂治疗的疗效, objectType=article, longId=291958, objectId=864c29195801, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=864c29195801, replyNumber=0, likeNumber=110, createdTime=2021-12-17, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=864c29195801, moduleTitle=Thorac Cancer：EGFR突变肺癌EGFR-TKIs治疗进展后应用免疫检查点抑制剂治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=864c29195801)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384242, encodeId=f59c1384242e3, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=APOLLO研究荣登JTO！中国原研三代EGFR-TKI阿美替尼以优异疗效数据惠及更多中国患者, objectType=article, longId=291811, objectId=3a262918115e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a262918115e, replyNumber=0, likeNumber=85, createdTime=2021-12-16, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a262918115e, moduleTitle=APOLLO研究荣登JTO！中国原研三代EGFR-TKI阿美替尼以优异疗效数据惠及更多中国患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a262918115e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384241, encodeId=661f13842412b, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Front Oncol：EGFR突变NSCLC患者使用EGFR-TKI进展后一线使用免疫治疗可能可改善患者预后, objectType=article, longId=221235, objectId=6ad622123581, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ad622123581, replyNumber=0, likeNumber=97, createdTime=2021-11-30, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ad622123581, moduleTitle=Front Oncol：EGFR突变NSCLC患者使用EGFR-TKI进展后一线使用免疫治疗可能可改善患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ad622123581)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384240, encodeId=2ac11384240c3, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Thorac Cancer： EGFR-TKIs提前应用可改善不可切除的III期EGFR突变肺腺癌的预后, objectType=article, longId=220997, objectId=b57822099e0a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b57822099e0a, replyNumber=0, likeNumber=91, createdTime=2021-11-26, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b57822099e0a, moduleTitle=Thorac Cancer： EGFR-TKIs提前应用可改善不可切除的III期EGFR突变肺腺癌的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b57822099e0a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384239, encodeId=f8e7138423926, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=解毒复正汤联合EGFR-TKIs对老年晚期肺癌患者的临床疗效观察, objectType=article, longId=220637, objectId=011e22063e38, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=011e22063e38, replyNumber=0, likeNumber=68, createdTime=2021-11-21, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=011e22063e38, moduleTitle=解毒复正汤联合EGFR-TKIs对老年晚期肺癌患者的临床疗效观察, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=011e22063e38)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384238, encodeId=7164138423831, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Clin Cancer Res：第三代EGFR-TKI Abvertinib治疗EGFR T790M+ NSCLC的活性和安全性, objectType=article, longId=220039, objectId=bb122200396e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb122200396e, replyNumber=0, likeNumber=0, createdTime=2021-11-11, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb122200396e, moduleTitle=Clin Cancer Res：第三代EGFR-TKI Abvertinib治疗EGFR T790M+ NSCLC的活性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb122200396e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384237, encodeId=8887138423e22, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Front Oncol： EGFR-TKIs新辅助治疗可手术切除NSCLC患者的疗效和安全性, objectType=article, longId=218184, objectId=5824218184a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5824218184a3, replyNumber=0, likeNumber=96, createdTime=2021-10-08, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5824218184a3, moduleTitle=Front Oncol： EGFR-TKIs新辅助治疗可手术切除NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5824218184a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384236, encodeId=6a2c1384236b0, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Front Oncol：EGFR突变NSCLC患者EGFR-TKI治疗进展后MET扩增患者的不同治疗策略的疗效探索, objectType=article, longId=218122, objectId=df5c21812297, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df5c21812297, replyNumber=0, likeNumber=71, createdTime=2021-10-06, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df5c21812297, moduleTitle=Front Oncol：EGFR突变NSCLC患者EGFR-TKI治疗进展后MET扩增患者的不同治疗策略的疗效探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df5c21812297)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384235, encodeId=89ae1384235e7, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效 , objectType=article, longId=217043, objectId=644421e04318, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=644421e04318, replyNumber=0, likeNumber=69, createdTime=2021-09-15, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=644421e04318, moduleTitle=J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=644421e04318)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384234, encodeId=d57d13842346c, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Eur Urol：立体定向放疗可改善接受TKI治疗的寡进展性mRCC患者的治疗效果, objectType=article, longId=216261, objectId=ba64216261c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba64216261c5, replyNumber=0, likeNumber=67, createdTime=2021-08-26, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba64216261c5, moduleTitle=Eur Urol：立体定向放疗可改善接受TKI治疗的寡进展性mRCC患者的治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba64216261c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384233, encodeId=995e1384233d7, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Cancer Commun：一线VEGFR-TKI失败的mRCC患者中，二线axitinib联合抗PD-1抗体或axitinib单药治疗的疗效, objectType=article, longId=215476, objectId=dc262154e628, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc262154e628, replyNumber=0, likeNumber=85, createdTime=2021-08-10, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc262154e628, moduleTitle=Cancer Commun：一线VEGFR-TKI失败的mRCC患者中，二线axitinib联合抗PD-1抗体或axitinib单药治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc262154e628)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384232, encodeId=83d71384232bd, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=J Thorac Oncol：EGFR 突变NSCLC脑膜转移患者TKI抑制剂进展后鞘内注射培美曲塞联合地塞米松的疗效和安全性, objectType=article, longId=214414, objectId=2f7c2144147c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f7c2144147c, replyNumber=0, likeNumber=82, createdTime=2021-07-21, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f7c2144147c, moduleTitle=J Thorac Oncol：EGFR 突变NSCLC脑膜转移患者TKI抑制剂进展后鞘内注射培美曲塞联合地塞米松的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f7c2144147c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384231, encodeId=27ff13842314f, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估, objectType=article, longId=211606, objectId=ff0121160699, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff0121160699, replyNumber=0, likeNumber=77, createdTime=2021-05-22, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff0121160699, moduleTitle=Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff0121160699)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384230, encodeId=e28a138423057, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Eur J Cancer: 循环肿瘤DNA（ctDNA）鉴别EGFR突变的NSCLC从EGFR-TKI连续治疗中获益的人群, objectType=article, longId=211422, objectId=34082114222e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34082114222e, replyNumber=0, likeNumber=95, createdTime=2021-05-18, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34082114222e, moduleTitle=Eur J Cancer: 循环肿瘤DNA（ctDNA）鉴别EGFR突变的NSCLC从EGFR-TKI连续治疗中获益的人群, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34082114222e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384229, encodeId=162e13842291e, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Clin Cancer Res：一种新的可预测髓系白血病TKI耐药的CIP2A突变体(NOCIVA), objectType=article, longId=208162, objectId=b515208162a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b515208162a0, replyNumber=0, likeNumber=73, createdTime=2021-03-09, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b515208162a0, moduleTitle=Clin Cancer Res：一种新的可预测髓系白血病TKI耐药的CIP2A突变体(NOCIVA), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b515208162a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384228, encodeId=b84813842283a, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=艾力斯三代EGFR-TKI甲磺酸伏美替尼获NMPA批准上市, objectType=article, longId=208133, objectId=ea64208133ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea64208133ab, replyNumber=0, likeNumber=68, createdTime=2021-03-09, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea64208133ab, moduleTitle=艾力斯三代EGFR-TKI甲磺酸伏美替尼获NMPA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea64208133ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384227, encodeId=8b28138422e91, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=第二个国产三代EGFR-TKI获批上市, objectType=article, longId=208092, objectId=47f52080927e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47f52080927e, replyNumber=0, likeNumber=76, createdTime=2021-03-09, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47f52080927e, moduleTitle=第二个国产三代EGFR-TKI获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47f52080927e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384226, encodeId=cbc4138422629, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Ann Oncol：劳拉替尼用于二代TKI治疗过的ALK阳性NSCLC患者的颅内外疗效, objectType=article, longId=207814, objectId=aa0620e814a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa0620e814a1, replyNumber=0, likeNumber=75, createdTime=2021-03-03, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa0620e814a1, moduleTitle=Ann Oncol：劳拉替尼用于二代TKI治疗过的ALK阳性NSCLC患者的颅内外疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa0620e814a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384225, encodeId=4556138422545, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=PD-1单抗Opdivo联合TKI抑制剂Cabometyx治疗肾癌，获得FDA优先评审, objectType=article, longId=202354, objectId=f8f120235495, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8f120235495, replyNumber=0, likeNumber=0, createdTime=2020-10-23, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8f120235495, moduleTitle=PD-1单抗Opdivo联合TKI抑制剂Cabometyx治疗肾癌，获得FDA优先评审, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8f120235495)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384224, encodeId=411f1384224cb, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Clini Cancer Research：二代ROS1-TKI，repotrectinib，治疗初治或ROS1突变的NSCLC, objectType=article, longId=197063, objectId=3fa819e06301, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fa819e06301, replyNumber=0, likeNumber=91, createdTime=2020-07-06, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fa819e06301, moduleTitle=Clini Cancer Research：二代ROS1-TKI，repotrectinib，治疗初治或ROS1突变的NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fa819e06301)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TKI

2020-05-29

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Thorac Cancer：EGFR突变肺癌EGFR-TKIs治疗进展后应用免疫检查点抑制剂治疗的疗效

2021-12-17

lsj628 (审核中...)

前往app查看评论内容

#TKI#

APOLLO研究荣登JTO！中国原研三代EGFR-TKI阿美替尼以优异疗效数据惠及更多中国患者

2021-12-16

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Front Oncol：EGFR突变NSCLC患者使用EGFR-TKI进展后一线使用免疫治疗可能可改善患者预后

2021-11-30

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Thorac Cancer： EGFR-TKIs提前应用可改善不可切除的III期EGFR突变肺腺癌的预后

2021-11-26

lsj628 (审核中...)

前往app查看评论内容

#TKI#

解毒复正汤联合EGFR-TKIs对老年晚期肺癌患者的临床疗效观察

2021-11-21

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Clin Cancer Res：第三代EGFR-TKI Abvertinib治疗EGFR T790M+ NSCLC的活性和安全性

2021-11-11

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Front Oncol： EGFR-TKIs新辅助治疗可手术切除NSCLC患者的疗效和安全性

2021-10-08

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Front Oncol：EGFR突变NSCLC患者EGFR-TKI治疗进展后MET扩增患者的不同治疗策略的疗效探索

2021-10-06

lsj628 (审核中...)

前往app查看评论内容

#TKI#

J Thorac Oncol：CNS渗透性TKI单药vs TKI+放疗治疗EGFR/ALK阳性NSCLC脑转移患者的疗效

2021-09-15

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Eur Urol：立体定向放疗可改善接受TKI治疗的寡进展性mRCC患者的治疗效果

2021-08-26

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Cancer Commun：一线VEGFR-TKI失败的mRCC患者中，二线axitinib联合抗PD-1抗体或axitinib单药治疗的疗效

2021-08-10

lsj628 (审核中...)

前往app查看评论内容

#TKI#

J Thorac Oncol：EGFR 突变NSCLC脑膜转移患者TKI抑制剂进展后鞘内注射培美曲塞联合地塞米松的疗效和安全性

2021-07-21

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Liver Cancer: 酪氨酸激酶抑制剂（TKI）联合PD1抑制剂对初始不可切除肝细胞癌（HCC）患者的降期以及手术切除率疗效评估

2021-05-22

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Eur J Cancer: 循环肿瘤DNA（ctDNA）鉴别EGFR突变的NSCLC从EGFR-TKI连续治疗中获益的人群

2021-05-18

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Clin Cancer Res：一种新的可预测髓系白血病TKI耐药的CIP2A突变体(NOCIVA)

2021-03-09

lsj628 (审核中...)

前往app查看评论内容

#TKI#

艾力斯三代EGFR-TKI甲磺酸伏美替尼获NMPA批准上市

2021-03-09

lsj628 (审核中...)

前往app查看评论内容

#TKI#

第二个国产三代EGFR-TKI获批上市

2021-03-09

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Ann Oncol：劳拉替尼用于二代TKI治疗过的ALK阳性NSCLC患者的颅内外疗效

2021-03-03

lsj628 (审核中...)

前往app查看评论内容

#TKI#

PD-1单抗Opdivo联合TKI抑制剂Cabometyx治疗肾癌，获得FDA优先评审

2020-10-23

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Clini Cancer Research：二代ROS1-TKI，repotrectinib，治疗初治或ROS1突变的NSCLC

2020-07-06

科室
- - 订阅+
  - 更多科室
工具
服务